MedTrace Logo

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

NCT02808572 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2022-01-04

No results posted yet for this study

Summary

To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.

Conditions

Interventions

BIOLOGICAL

Plasma osteoprotegerin level

dosage of plasma osteoprotegerin

BIOLOGICAL

Plasma fibroblast growth factor 23 level

dosage of plasma fibroblast growth factor 23

PROCEDURE

Vascular calcification score

measurement of vascular calcification score by multidetection computerized tomography

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Jean-Paul CRISTOL, Prof · CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-12
Primary Completion
2024-03-31
Completion
2031-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02808572 on ClinicalTrials.gov